DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, is set to announce its third quarter 2025 financial results on November 12, 2025, after market hours. The announcement will be followed by a live conference call the next day, November 13, at 8:00 AM ET (7:00 AM CT), where the company will provide significant updates on its business and discuss financial performance.

The conference call can be accessed via a dedicated web link or by dialing in. Interested parties are encouraged to log in or call in about 15 minutes early, ensuring they have access to the entire presentation. The event will also be available for replay on the company’s website for one year after the call, highlighting DiaMedica's commitment to transparency and accessibility for its investors. Additionally, a telephonic replay will be available until November 20, providing flexibility for those who wish to listen later.

DiaMedica is focused on developing innovative treatments addressing serious ischemic diseases, including preeclampsia and acute ischemic stroke. The company’s lead product candidate, DM199, represents a groundbreaking approach as the first pharmaceutically active recombinant form of the KLK1 protein, a treatment already established in Asia for various vascular diseases. This focus underlines the company's mission to enhance the lives of patients facing such critical health conditions.

For further corporate information or media inquiries, investors and media representatives can reach out through the provided contact details. As DiaMedica moves forward with its clinical developments, stakeholders will be eager to assess the outcomes of the upcoming financial results and business developments.

As DiaMedica Therapeutics Inc. (Nasdaq: DMAC) prepares to release its third quarter 2025 financial results on November 12th after market close, investors should focus on several critical aspects that could influence the stock’s performance in the short term.

First, the company's lead candidate, DM199, is positioned favorably within the biopharmaceutical landscape, targeting significant unmet medical needs in preeclampsia and acute ischemic stroke. The emphasis on DM199 as a novel synthetic form of the KLK1 protein could provide strong market differentiation, especially since therapeutic options are limited for these serious conditions.

Investors should monitor the financial results closely for insights into cash burn rates and any updates on funding or future trials. Given the early-stage nature of its development pipeline, understanding the company’s financial health is crucial. An effective management of resources will be vital to maintaining momentum, as clinical trials are expensive and time-consuming.

Additionally, the market's response could hinge on the business update provided during the conference call on November 13th. It's essential for the management team to communicate clinical milestones achieved since the last update, any strategic partnerships formed, or progress with regulatory agencies. Positive developments in these areas could bolster investor confidence and drive stock price appreciation.

Lastly, potential market sentiment should be observed leading up to the earnings call. As with many biotech companies, stock price volatility can precede significant announcements. Engaging in careful analysis and timing trades around the earnings release could present opportunities for both long-term investors and short-term traders.

In conclusion, prepare for potential volatility around the earnings announcement, focus on cash management, and stay attuned to clinical and strategic developments that could influence DiaMedica's stock performance moving forward.